DNB Carnegie Access: EQL Pharma: Delivery delays lower 2025/26e growth to ~15%
DNB Carnegie has published a new flash comment on EQL Pharma following recent news flow.
To access the full report and subscribe to future updates, visit https://www.carnegie.se/en/commissioned-research/eql-pharma/